UNI-MB - logo
UMNIK - logo
 
Univerzitetni klinični center Maribor (SBMB)
  • Research work at the Department of gynecologic and breast oncology of Maribor teaching hospital
    Takač, Iztok
    A comprehensive reasearch work has been established at the Department of Gynecologic and Breast Oncology of Maribor Teaching Hospital. Among the most important recently conducted studies are a ... multinational study in patients with ovarian carcinoma using the HMFG1 antibody labeled with [sup] 90Yttrium (R1549), study code: SMART), a multi-national randomized Phase III GCIG Intergroup Study comparing 1st line chemotherapy with Gemcitabine Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in previously untreated patients with epithelial ovarian cancer FIGO stages I - IV (study code OVAR-9), a multicenter phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC-->T) as adjuvant treatment of operable breast cancer Her2neu negative patients with positive axillary lymph nodes (study code BCIRG 005) and a multicenter phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) and with docetaxel, carboplatin and trastuzumab (TCH) in the adjuvant treatment of nodepositive and high risk node negative patients with operable breast cancer containing the her2neu alteration (study code BCIRG 006). All of these are very important multicentric and multiinstitutional studies in which several patients have been enrolled.
    Vir: Proceedings of the Exchange Programme of Trainees in Obstetrics and Gynaecology at Maribor Teaching Hospital, 22 to 25 November 2004 (Str. 63-76)
    Vrsta gradiva - prispevek na konferenci ; neleposlovje za odrasle
    Leto - 2004
    Jezik - angleški
    COBISS.SI-ID - 1749567

Vnos na polico